Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022026 | 1.00 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4023694 | 0.89 | ALDH1A1 (0.44) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4021968 | 0.89 | ALDH1A1 (0.44) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4021223 | 0.89 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4021972 | 0.89 | ALDH1A1 (0.44) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4021226 | 0.89 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4020218 | 0.88 | MAPT (0.39) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4020222 | 0.88 | MAPT (0.39) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4780063 | 0.88 | ALDH1A1 (0.46) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL4777781 | 0.88 | ALDH1A1 (0.46) | MEN1KMT2ASMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | MEN1 77/4885KMT2A 2820/4885SMN1; SMN2 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.